Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06255665
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-02-05
Brief Title:
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
Sponsor:
Janssen Research Development LLC
Organization:
Janssen Research Development LLC
Study Overview
Official Title:
A Phase 1 Study of JNJ-79032421 a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine recommended phase 2 doses RP2Ds of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2Ds
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-504896-26-00 | REGISTRY | EUCT number | None |